ARGX vs LIVN
argenx SE vs LivaNova — AI-powered side-by-side comparison
| Metric | ARGX | LIVN |
|---|
| AI Score |
68
|
70
|
| Price |
$851.51
|
$82.25
|
| P/E Ratio |
30.62×
|
23.83×
|
| ROE |
17.6%
|
-20.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
68.2%
|
| Debt / Equity |
0.01×
|
0.27×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.5
|
60.6
|
| Beta |
-0.022
|
0.872
|
| Expected Upside |
+0.0%
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus LIVN.
LIVN leads by 2 points.
LIVN scores 70/100 (Buy) versus ARGX at 68/100 (Buy).
ARGX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.